Zenas BioPharma Highlights Strong Q1 Progress and Financing

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest update is out from Zenas BioPharma, Inc. ( (ZBIO) ). On May 11, 2026, Zenas BioPharma stockholders approved two Class II directors for new three-year terms, accepted the resignation of director Tomas Kiselak, and reduced the board size by one, while also ratifying Ernst & Young as the auditor for the 2026 fiscal year. On May 13, 2026, the company reported a sharp year-on-year rise in first-quarter R&D and G&A spending as it advanced obexelimab toward U.S. and European marketing applications, completed enrollment in its Phase 2 SLE trial, initiated a Phase 1 study of oral IL-17 inhibitor ZB021, continued global Phase 3 programs for orelabrutinib in progressive multiple sclerosis, and bolstered its balance sheet with $419 million in equity and convertible note offerings plus a $250 million debt facility, extending its projected cash runway into 2029. Positive Phase 3 data from the INDIGO trial showed obexelimab cut IgG4-related disease flare risk by 56% versus placebo over 52 weeks and will be highlighted in a June 4, 2026 oral presentation at the EULAR congress in London, reinforcing the asset’s potential as a first-in-class therapy. With more than $718 million in cash and investments at March 31, 2026, and multiple late- and early-stage trials underway, Zenas is positioning itself for a potential commercial launch of obexelimab and a broader autoimmune portfolio, though the rising operating expenses underscore growing execution and regulatory risks that investors will watch closely. The most recent analyst rating on (ZBIO) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page. Spark’s Take on ZBIO Stock According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral. The score is driven primarily by weak financial performance (large losses, declining revenue, and heavy cash burn) and bearish technicals (price below key moving averages and negative MACD). These are partially offset by a low-debt balance sheet and a strong positive corporate event (successful Phase 3 data with stated plans for near-term regulatory filings). To see Spark’s full report on ZBIO stock, click here. More about Zenas BioPharma, Inc. Zenas BioPharma, Inc. is a Nasdaq-listed, clinical-stage global biopharmaceutical company focused on developing and commercializing transformative therapies for patients with autoimmune and chronic inflammatory diseases. Its pipeline centers on obexelimab, a CD-19 and FcgRIIb inhibitor for IgG4-related disease and systemic lupus erythematosus, alongside CNS-penetrant BTK inhibitor orelabrutinib for progressive multiple sclerosis and early-stage oral immunology assets such as IL-17 inhibitor ZB021 and TYK2-JH2 inhibitor ZB022. Average Trading Volume: 703,713 Technical Sentiment Signal: Sell Current Market Cap: $1.1B